丁氧基羰基-D-5-溴尿嘧啶 | 77004-75-2

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 丁氧基羰基-D-5-溴尿嘧啶
• 中文别名: N-BOC-D-天冬氨酸1-叔丁酯；N-叔丁氧羰基-D-天冬氨酸1-叔丁酯；(R)-3-(Boc-氨基)-4-(叔丁氧基)-4-氧代丁酸；BOC-D-天冬氨酸叔丁酯
• 英文名称: Boc-D-Asp-OtBu
• 英文别名: N-Boc-D-aspartic acid 1-tert butyl ester；(R)-4-(tert-butoxy)-3-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid；(3R)-4-[(2-methylpropan-2-yl)oxy]-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid
• CAS: 77004-75-2
• 化学式: C₁₃H₂₃NO₆
• 分子量: 289.329
• InChiKey: RAUQRYTYJIYLTF-MRVPVSSYSA-N

物化性质

• 沸点：
  429.0±40.0 °C(Predicted)
• 密度：
  1.139

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-D-Asp-OtBu
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-D-Asp-OtBu
CAS number: 77004-75-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H23NO6
Molecular weight: 289.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  丁氧基羰基-D-5-溴尿嘧啶 在 sodium tetrahydroborate 、 四溴化碳 、 氯甲酸乙酯 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 6.5h， 生成 4-(溴甲基)苄基氨基甲酸叔丁酯
  参考文献：
  名称：

  (-)-nocardicins AG 的全合成：一种生物遗传学方法

  摘要：

  已知的诺卡菌素 AG 已被合成，其中有几种是首次合成，具有高度的几何和立体异构纯度。合成通过 (-)-3-aminocardicate 叔丁酯 (14) 的中心中间体进行，该中间体是在受保护的 L-seryl-D-(p-羟基苯基) 甘氨酸的生物遗传学图案、改良的 Mitsunobu 环脱水反应中制备的二肽

  DOI：

  10.1021/ja00158a040
• 作为产物：
  描述：

  tert-butyl 2-[(benzyloxy)carbonyl]-1-(tert-butoxycarbonyl)ethylcarbamate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 以100%的产率得到丁氧基羰基-D-5-溴尿嘧啶
  参考文献：
  名称：

  光学纯 4-氟-谷氨酰胺的合成作为潜在的肿瘤代谢成像剂

  摘要：

  通过利用 Passerini 三组分反应开发了一种用于制备所有四种立体异构 4-氟-谷氨酰胺的通用合成路线。有效构建了 4-取代谷氨酰胺衍生物的骨架。随后的四步反应，以“中和”的 TASF 氟化为重点，提供了具有高产率和优异光学纯度的所需产物。使用 18-crown-6/KHCO(3) 或 K[222]/K(2)CO(3) 催化系统也成功地制备了光学纯氟 18 标记的 4-氟谷氨酰胺。使用 9L 肿瘤细胞和 SF188(Bcl-xL) 肿瘤细胞（一种源自胶质母细胞瘤的谷氨酰胺成瘾肿瘤）进行的初步细胞摄取和抑制研究为它们与正电子发射断层扫描 (PET) 结合用于体内成像的潜在应用提供了强有力的证据。肿瘤，

  DOI：

  10.1021/ja109203d

文献信息

• TRIAZOLE ANTIMICROBIAL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：WUHAN LL SCIENCE AND TECHNOLOG DEVELOPMENT CO.,LTD.

  公开号：US20190382375A1

  公开（公告）日：2019-12-19

  The present disclosure provides a triazole antibacterial derivative and a pharmaceutical composition thereof and a use thereof and in particular relates to a compound represented by the following formula (I), and a racemate, a stereoisomer, a tautomer, an oxynitride or a pharmaceutically acceptable salt thereof: The compound of the present disclosure has a desirable water solubility and can be formulated into an injection for use without adding a cosolvent having a potential safety risk (such as hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and the like), facilitating drug administration for patients, and greatly improving clinical safety. The drug can be used even by patients with moderate or severe renal impairment, thereby expanding the application scope of the drug.

  本公开提供了一种三唑类抗菌衍生物及其药物组合物和使用方法，特别涉及以下式(I)所代表的化合物，以及其外消旋体、立体异构体、互变异构体、氧氮化物或药学上可接受的盐： 本公开的化合物具有良好的水溶性，可以制成注射剂，无需添加潜在安全风险的共溶剂（如羟丙基-β-环糊精、磺丁基醚-β-环糊精等），有助于患者用药，极大地提高了临床安全性。该药物甚至可以供中度或重度肾功能损害的患者使用，从而扩大了药物的应用范围。
• [EN] BENZIMIDAZOLE OR INDOLE AMIDES AS INHIBITORS OF PIN1<br/>[FR] AMIDES DE BENZIMIDAZOLE OU D'INDOLE EN TANT QU'INHIBITEURS DE PIN1
  申请人：PFIZER

  公开号：WO2006040646A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (1) and to pharmaceutical compositions for treating such disorders that contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).

  这项发明涉及公式（1）的化合物，以及其药学上可接受的盐和溶剂化合物，其中变量在此处定义。该发明还涉及通过给予公式（1）的化合物来治疗哺乳动物中的异常细胞生长的方法，以及用于治疗包含公式（1）化合物的这类疾病的药物组合物。该发明还涉及制备公式（1）化合物的方法。
• Ynamide-Mediated Thiopeptide Synthesis
  作者：Jinhua Yang、Changliu Wang、Silin Xu、Junfeng Zhao

  DOI：10.1002/anie.201811586

  日期：2019.1.28

  two‐step strategy for thiopeptide bond formation with readily available monothiocarboxylic acids as thioacyl donors is described. The α‐thioacyloxyenamide intermediates formed from the ynamides and monothiocarboxylic acids can be purified, characterized, and stored. The balance between their activity and stability enables them to act as effective thioacylating reagents to afford thiopeptide bonds under mild

  不足的合成策略不足以将硫酰胺键位点引入肽主链，因此无法探索作为肽和蛋白质化学生物学工具的硫酰胺替代物的全部潜力。描述了一种新颖的由酰胺介导的两步策略，用于以易于获得的单硫代羧酸作为硫代酰基供体的硫肽键形成。由乙酰胺和一硫代羧酸形成的α-硫代酰氧烯酰胺中间体可以进行纯化，表征和储存。它们的活性和稳定性之间的平衡使它们能够充当有效的硫酰化试剂，在温和的反应条件下提供硫肽键。氨基酸官能团，例如OH，CONH 2，并且在巯基肽合成过程中不需要保护吲哚NH基团。这种策略的模块化性质使得在溶液和固相中都可以将硫酰胺键定点结合到肽主链中。
• MASP-2 INHIBITORS AND METHODS OF USE
  申请人：Omeros Corporation

  公开号：US20210171531A1

  公开（公告）日：2021-06-10

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物，以及制造和使用这些化合物的方法。
• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2019104011A1

  公开（公告）日：2019-05-31

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本发明涉及化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与鞘氨醇半乳糖基转移酶（CGT）相关疾病或失调的方法，例如，例如，溶酶体贮积病。溶酶体贮积病的例子包括，例如，克拉伯病和异染性脑白质营养不良。